Market Intelligence, Preclinical Progress, and High-Purity Reagents for CCR4-NOT Complex Targeting in Oncology and Beyond.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CNOT3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CNOT3 Full-Length, ARM Domain & Mutant Proteins (R251C, R233C) High purity (>95%), Sequence Verified. HEK293/E.coli expression. Endotoxin <1EU/µg. |
View CNOT3 Products |
| Mutant Panel | CNOT3 AML-Associated Mutants (R251C, R233C) Sequence-verified cancer variants for mechanistic and resistance studies. |
View CNOT3 Products |
| Gene Delivery | CNOT3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression. |
View CNOT3 Products |
| Benchmark Ab | Anti-CNOT3 Recombinant Antibody (Research Grade) Recombinant positive control for IP, WB, IF validation. |
View CNOT3 Products |
| Validator | CNOT3 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View CNOT3 Products |
| Related Target: CNOT1 | CNOT1 (Scaffold Subunit) Direct interactor; essential for CNOT3 recruitment and PPI disruption assays. |
View CNOT1 Products |
| Related Target: CNOT2 | CNOT2 (Paralogous Subunit) Required for selectivity counter-screening within the CCR4-NOT complex. |
View CNOT2 Products |
| Related Target: CNOT7 | CNOT7 (CAF1 Deadenylase) Downstream enzymatic node; functional validation and pathway readouts. |
View CNOT7 Products |
| Related Target: TOB1 | TOB1 (Antiproliferative Protein) Key interactor with CNOT3 in transcriptional regulation. |
View TOB1 Products |
| Related Target: MYC | MYC (Oncogene) Downstream effector regulated by CNOT3 deadenylase activity; useful as pharmacodynamic readout. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular targeting (PROTAC/Molecular Glue) | High-purity Full-Length CNOT3 (>95%) with native folding. Endotoxin <1EU/µg. |
| Cancer mutation validation (R251C, R233C) | Mass spec verified mutant proteins; wild-type vs mutant comparative panels for thermal shift and PPI assays. |
| CCR4-NOT complex assembly screening | Co-expression compatible; CNOT1, CNOT2, CNOT3 available for heterotrimeric complex reconstitution. |
| Selectivity over paralogous NOT subunits | Homolog panel (CNOT1, CNOT2, CNOT7) verified by mass spec; ARM domain vs paralog selectivity profiling. |
| Cell-based target engagement | Lentivirus ORF and shRNA vectors for stable line construction in mammalian systems. |
| Knockdown verification | Validated siRNA included as specificity controls in cellular assays. |
Live CNOT3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CNOT3 therapeutics is intensifying as researchers recognize the CCR4-NOT complex's critical role in mRNA deadenylation and gene regulation. With recurrent CNOT3 mutations (R251C, R233C) in Acute Myeloid Leukemia (AML) revealing oncogenic dependencies, first-generation molecular glues and PROTACs targeting the CNOT1-CNOT3 interface are entering preclinical development. The next wave of R&D is targeting synthetic lethal combinations with CNOT3 loss-of-function and specific epigenetic vulnerabilities, as well as expansion into solid tumors and metabolic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue Degraders | Emerging biotech & academia | AML (R251C mutant), Solid Tumors | CNOT1-CNOT3 PPI disruption assay (Need high-purity ARM domain & mutant proteins) |
| PROTAC | Academic consortia, early-stage ventures | T-ALL, Solid Tumors | Ternary complex formation (Need full-length CNOT3 + E3 ligase components) |
| Small Molecule (PPI) | Early discovery programs | Oncology | NOT box interface disruption (Need domain-truncated CNOT3 proteins) |
| RNAi / ASO | Discovery labs | Metabolic Diseases | Knockdown validation (Need validated siRNA & lentivirus) |
| CRISPR/Synthetic Lethal | Academic consortia | Myeloid Malignancies | Functional genomics (Need CNOT3 knockout/knockdown tools) |
Key Mutations and Resistance Insights
Clinical studies have identified recurrent CNOT3 mutations in AML (R251C, R233C) that disrupt CNOT1 binding and alter mRNA stability. As first-in-class PPI inhibitors and degraders advance, acquired resistance may arise from compensatory mutations in CNOT2, CNOT7, or secondary CNOT3 mutations. TarMart provides mutant protein panels (single and double mutants) for mechanistic studies and resistance profiling. Additionally, TOB1 and MYC serve as critical downstream interactors for pharmacodynamic readouts.